IBM/PHYSIOME SIGN SUPERCOMPUTING/BIOLOGICAL MODELING PACT.
Physiome Sciences and its development collaborator, the University of Auckland in New Zealand will receive two of the first shipments of IBM's new eServer POWER4-based supercomputers. The system will enable Physiome Sciences to speed up its current capability to simulate complex models of cells, tissues and organs, and simulate the behavior of diseases such as diabetes, hypertension and asthma.
"Physiome Sciences's goal is to incorporate information from protein pathways into computerized models of cells, organs, and disease states -- laying the infrastructure for virtual drug discovery," said Dr. Jeremy Levin, CEO of Physiome Sciences. "Our alliance with IBM will speed this process and enhance our technology capability to develop the leading in silico solutions."
For pharmaceutical and other biomedical researchers using Physiome Sciences's simulation technology, the benefits will include significant time and cost savings, and better predictions about the effects of drug candidates on animals and humans. Users will be able to perform biological modeling that yields proprietary, company-specific insights into drug targets and disease mechanisms.
The alliance will enable Physiome Sciences to enhance its product offerings, which include CardioPrism(TM) and PathwayPrism(TM). These technology platforms address critical drug discovery requirements in data integration, data analysis and modeling, resulting in better target identification and analysis of effects of novel drugs and drug toxicity.
"IBM's leadership in such areas as high-performance computing and research complements Physiome Sciences's expertise in biological modeling," said Dr. James Coffin, director, IBM Life Sciences Solutions. "Our complementary strengths will enable researchers to draw on cutting edge technologies to advance medical research and speed up the drug discovery process."
Through the agreement, IBM becomes Physiome Sciences's preferred information technology supplier for high-performance computing, professional services and data integration. In addition, IBM will license the PathwayPrism(TM) technology from Physiome Sciences for its internal use. PathwayPrism(TM) utilizes Physiome Sciences's revolutionary In-SilicoCell(TM) technology for building biological models. Physiome Sciences will write wrappers for its product offerings to run on IBM offerings, including IBM DB2 Universal Database and DiscoveryLink integration software.
Further, IBM and Physiome Sciences will explore research collaborations to integrate complementary technologies in such areas as pattern discovery, gene expression analysis, and signal transduction pathways, which map biological activities within cells. IBM also will work with Physiome Sciences to promote open standards such as the CellML(TM), an XML-based language to develop computer models of cells, tissues and organs.
Designed to provide industry-leading performance for both commercial and technical workloads, POWER4-based systems will feature groundbreaking new technologies, such as the world's first computer chip containing two processors; more than an order of magnitude improvement in bandwidth over today's systems; and a new method of connecting devices that dramatically increases scalability by combining the benefits of leading architectures for server communications.
About IBM Life Sciences
IBM Life Sciences brings together IBM resources -- from research and e-business expertise to data and storage management and high-performance computing -- to deliver new solutions to the life sciences market, including biotechnology, genomic, e-health, pharmaceutical and agri-business companies. For more information on IBM Life Sciences, visit http://www.ibm.com/solutions/lifesciences.
About Physiome Sciences
Physiome Sciences, Inc., a privately held Princeton-based company, is a leader in the commercial development of software tools, proprietary databases, and web applications for simulating biological processes. This biological operating system can be harnessed to model cells, tissues and organs, in a virtual setting, enabling scientists to generate predictive information using their own data. Drug developers, for example, already use Physiome's operating system and models to predict the effects of specific drugs on animals and humans. This greatly speeds the selection of drugs for entry into human trials. The selection process becomes more rational and potentially increases drug quality at an early state of development.
The CellML(TM) language was developed as an open standard that is available free of charge to all users. Additional information can be obtained by visiting the CellML(TM) website at http://www.cellml.org. Additional information on the bioengineering group at the University of Auckland in New Zealand can be obtained by visiting the web site at http://www.esc.auckland.ac.nz/sites/bioeng. For additional information on Physiome Sciences' products, e-mail the company at Product_Info@physiome.com. This release and additional news about Physiome can be obtained by visiting the company's web site at http://www.physiome.com/.
For more information, call (914)766-1180 or visit http://www.ibm.com/solutions/lifesciences or http://www.physiome.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 1, 2001|
|Previous Article:||VERTEX INSTALLS SUPERCOMPUTER TO SPEED DRUG DISCOVERY.|
|Next Article:||SUN'S 24-WAY MIDFRAME SERVER SETS WORLD RECORD.|